

**NATIONAL EXPERT PANEL ON  
NEW AND EMERGING  
INFECTIONS**

**2008 Annual Report**

## Contents

<b>Introduction</b>	4
Background and role of NEPNEI	
Report period	
Meetings held	
Code of Practice	
NEPNEI membership in 2008	
Summary list of letters written by the Chair	
<b>Horizon scanning for emerging infections</b>	7
Human Animal Infections and Risk Surveillance (HAIRS) and roles and responsibilities of NEPNEI	
HAIRS topics brought to the attention of the Panel	
<b>Topics considered by NEPNEI in 2008</b>	9
New items of business	
<ul style="list-style-type: none"><li>• Anthrax</li><li>• Hepatitis B and C viral resistance</li><li>• Highly Pathogenic Avian Influenza (HPAI) H7N7</li><li>• International Health Regulations</li><li>• Measles</li><li>• New human viruses and the UK's ability to detect them</li><li>• Novel pathogenic Old World arenavirus outbreak South Africa</li><li>• Scientific Advisory Committee on the Safety of Blood, Tissues and Organs</li><li>• UK High containment level research facilities</li><li>• UK-wide remit of NEPNEI</li></ul>	
Reviewed or updated items	11
<ul style="list-style-type: none"><li>• Atypical scrapie</li><li>• Department of Health Research Strategy</li><li>• Extended Spectrum Beta Lactamases (ESBL)-producing <i>Escherichia</i></li></ul>	

*coli*

- Extensively drug-resistant (XDR) and Multi-drug resistant (MDR) tuberculosis
- Meticillin resistant *Staphylococcus aureus* (MRSA) in animals
- Pandemic influenza
- West Nile Virus

**Annexes**

14

Annex A: Membership lists

Annex B: Register of members' interests

Annex C: Agendas for meetings

Annex D: Index of abbreviations

## **Introduction**

An emerging infection is either a newly recognised, clinically distinct infectious disease or a known disease whose reported incidence within the past two decades is increasing in a given place or among a specific population.

### **Background and role of NEPNEI**

The National Expert Panel on New and Emerging Infections (NEPNEI) was established in 2003, to provide independent expert advice to the England Chief Medical Officer (CMO) on the public health risk from new and emerging infections. The Panel assesses risks based upon scientific evidence and best available clinical and epidemiological expertise. The Panel seeks wider input from experts in their field to augment its own expertise as appropriate. The secretariat is provided by the Health Protection Agency (HPA) on behalf of the Department of Health.

The terms of reference of the Panel are to identify key areas for action and to advise on priorities by:

- Identifying emerging and potential infectious threats to public health both nationally and internationally;
- Placing emerging infections in the wider clinical and public health contexts;
- Advising on prevention and control measures;
- Prioritising areas for surveillance and for information needs;
- Advising on research, including technological development needs.

### **UK-wide remit of NEPNEI**

The Chief Medical Officer of each Devolved Administration (DA) has confirmed their wish to be informed of the Panel's discussions and conclusions and the DAs send observers to NEPNEI meetings.

### **Report period**

This report covers the period of January 1 to December 31 2008.

The Chair would very much like to thank all members of the Panel for their time, hard work and commitment over the last year.

### **Meetings held**

Meetings of NEPNEI were held on the following dates:

Tenth meeting - 5 June 2008

Eleventh meeting - 27 November 2008

The agendas for these meetings can be found in Annex C, and the minutes on the NEPNEI website (web address below).

### **Code of Practice**

The activities of the Panel are governed by a Code of Practice in line with Government policy on standards of public life. The Code sets out the roles and responsibilities of Members, the Chair and the secretariat, and covers terms of appointment, declarations of interests, the conduct of business and the seven principles of public life. The Code of Practice is published on the NEPNEI website.

### **NEPNEI Membership**

NEPNEI membership comprises:

- Serving Chairs of the following expert Advisory Committees with an interest in infectious diseases:
  - *Scientific Advisory Committee on Genetic Modification (contained use) (SACGM)*
  - *Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections (ARHAI)*
  - *Expert Advisory Group on Aids (EAGA)*
  - *Advisory Committee on Dangerous Pathogens (ACDP)*
  - *Joint Committee on Vaccination and Immunisation (JCVI)*
  - *Spongiform Encephalopathy Advisory Committee (SEAC)*

- *Advisory Committee on the Microbiological Safety of Food (ACMSF)*
- *Advisory Group on Hepatitis (AGH)*
- *Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO)*

- Individual members with specialist expertise in science or medicine; and
- A lay member

A full membership list for 2008 can be found in Annex A. The register of members' interests is in Annex B.

Further information about the Panel, including minutes of meetings and past Annual Reports, can be found on the NEPNEI website.

**NEPNEI website address:**

<http://www.dh.gov.uk/ab/NEPNEI/index.htm>

### **Horizon Scanning for emerging infections**

The scientific secretariat at the HPA undertakes horizon scanning activities to detect infections that may pose a significant public health threat to the UK population. A variety of information sources are monitored for reported events that may pose, or develop into, a public health threat to the UK population. A monthly summary of such events or incidents, both nationally and internationally, is produced for NEPNEI members.

### **Human Animal Infections and Risk Surveillance (HAIRS)**

The HAIRS group was established in February 2004 to provide a forum in which to identify and assess infections for their potential for interspecies transfer (particularly zoonotic infections). This multi-disciplinary, multi-agency group meets monthly to undertake risk assessments on behalf of NEPNEI. It is chaired by the HPA's scientific secretariat of NEPNEI. Members are drawn from the HPA, Defra, Veterinary Laboratories Agency, Department of Health, the National Public Health Service for Wales, Food Standards Agency, Health Protection Scotland (HPS), Animal Health, the Communicable Disease Surveillance Centre Northern Ireland (CDSC NI), the Scottish Executive and the Chair of NEPNEI. The HAIRS group assesses any risk to the UK population from infectious agents identified during the horizon scanning process, based upon a previously approved and adopted risk assessment algorithm.

For the benefit of new Members of the Panel, the Chair of HAIRS gave a presentation to the Panel on the remit of the group, horizon scanning and its risk assessment processes. NEPNEI Members found the work of the group extremely valuable and agreed that the processes used for horizon scanning and risk assessment were robust. It was agreed that only those risk assessments that had been rated as higher than 'low' would be presented to NEPNEI, given that Members had approved the methodology used for risk assessment. The Chair of NEPNEI attends HAIRS and can raise any issues or concerns with Panel Members .

## HAIRS topics brought to the attention of the Panel

### **Progressive Inflammatory Neuropathy**

The Panel was informed of a recently identified neurological syndrome, Progressive Inflammatory Neuropathy (PIN) among pork processing workers in the USA. PIN is associated with the use of compressed air for the removal of porcine brain tissue. The HAIRS group had alerted relevant clinicians (through the Association of British Neurologists) and discussed the issue with the US investigators. It is understood that compressed air extraction of pig's brains does not occur in the UK and no cases of PIN had been detected in the UK. The HAIRS group proposed no further active consideration of this syndrome. Panel members noted that this syndrome raised wider issues surrounding occupational exposure to zoonotic pathogens and the capacity to conduct enhanced surveillance in groups working with animals.

### **Novel *Brucella* species in marine mammals**

*Brucella* species have been isolated from a range of marine mammal species in the UK since they were first reported in 1994. Two new species were identified in 2008: *Brucella ceti* (for strains with cetaceans such as whales and dolphins as their preferred host) and *Brucella pinnipedialis* (for strains with pinnipeds such as seals and sea lions as their preferred host). The HAIRS group carried out a risk assessment of the zoonotic potential of these organisms in marine mammals in the UK. It was felt that the main risk would be to those working with cetaceans, particularly sick cetaceans, and that this occupational group should be alerted as to the existence of these new species. The Panel noted that it would also be useful to alert laboratories involved in the diagnosis of brucellosis, and to include information on the rapidity of the growth of these species in culture once this has been determined

Other incidents reported to the Panel for information included:

- *Waddlia chondrophila* in cattle
- Intestinal spirochaetosis in birds



## **Topics considered by the National Expert Panel on New and Emerging Infections in 2008**

### **New items of business**

#### Anthrax

The Panel was informed of a recent case of inhalation anthrax in London and its suspected link to imported animal hides used for drum making. The Health Protection Agency had coordinated a full investigation and implemented infection control measures.

#### Hepatitis B and C viral resistance

The Chair of the Advisory Group on Hepatitis (AGH) gave a presentation on hepatitis B and C antiviral resistance, demonstrating that drug resistant hepatitis B and C is increasing as a result of current drug monotherapy for treatment of these viruses, and concluding that combination therapies should be used from the outset. Members agreed that this change in clinical prescribing practice should be put in place quickly and recommended it be incorporated into National Institute for Clinical Excellence (NICE) guidelines forthwith. A letter was sent jointly from the Chairs of NEPNEI and AGH, expressing concern over the development of antiviral resistance in patients with chronic viral hepatitis treated with monotherapy, and recommending, from both committees, a move to combination therapy for the treatment of hepatitis B and C. NICE has acknowledged receipt of the letter and a further response is awaited.

#### Highly Pathogenic Avian Influenza (HPAI) H7N7

The Panel was updated on a UK outbreak of HPAI H7N7 in chickens in Oxford on June 5 2010. No human cases were detected and all those potentially exposed to the virus were traced and offered post-exposure prophylactic anti-viral medication.

### Measles

A member voiced concerns about the increase in confirmed cases of measles, particularly in London, and the low uptake of the vaccine. The Panel was provided with a written update regarding measles epidemiology and the measures being taken to reduce the prevalence of this disease in the UK.

### New human viruses and the UK's ability to detect them

The Panel reviewed the UK's capability to detect new pathogens which may not be picked up by standard diagnostic tests. Concern was expressed over the decreasing number of laboratories that are able to perform virus culture and electron microscopy, and the diminishing expertise and collaboration in this field. These diagnostic techniques are particularly important to detect previously unknown viruses as they are generic methods of viral detection rather than specific to a particular virus. The Chair wrote to the Chief Executive of the HPA to highlight this issue and to stress the importance of maintaining diagnostic capability for new and emerging infections.

### Novel pathogenic Old World arenavirus outbreak South Africa

Representatives from the National Institute of Communicable Diseases in South Africa updated the Panel, via videolink, on recent investigations into a cluster of cases of severe illness caused by a novel pathogenic arenavirus in southern Africa. The virus appears to be very virulent, with four of the five identified cases being fatal. The known risk of endemic infection is currently restricted to Zambia. The Panel assessed the potential impact on UK public health and concluded that the present situation does not necessitate a change to current UK guidance for the diagnosis and management of viral haemorrhagic fevers. However, it was noted that this guidance requires updating to reflect developments in patient care since it was originally published.

### Scientific Advisory Committee on the Safety of Blood, Tissues and Organs

The Panel was provided with an overview of the remit and work of this newly formed Committee which first met in January 2008.

### UK high containment level research facilities

The Panel were provided with two reports:

- The House of Commons Innovation, Universities Science and Skills Committee's review on biosecurity and capacity in the UK's high containment laboratories, and the Government's response to that report.
- The report of the independent review of the highest level microbiological containment facilities in the UK conducted by the HPA on behalf of the Medical Research Council. The Review Panel had been chaired by the Chair of Advisory Committee on Dangerous Pathogens.

### **Reviewed or updated items**

#### Atypical scrapie

The SEAC representative gave a presentation on atypical scrapie and unusual BSE cases in the UK. It was concluded that there was currently no evidence to suggest these conditions pose a significant new threat to human health requiring changes to current strategies but that there are insufficient data to conclude this definitively.

#### DH Research Strategy

Members received a presentation on the Department of Health's Research Strategy highlighting how new and emerging infections fit into the Department's overall research strategy. Members were reassured that research funding could be made available if an urgent and proven need were to arise for research into a new and emerging infection of UK public health concern.

#### Extended Spectrum Beta Lactamase (ESBL)-producing *Escherichia coli*

The Panel was informed that two groups have been established to deal with this issue: a joint ESBL Working Group between ARHAI and Defra's Antimicrobial Resistance Coordination (DARC) group, which will deal with food-producing animals, and a group tasked with developing guidelines for the initial management of patients and laboratory diagnosis of these organisms.

### Extensively drug-resistant (XDR) and Multi-drug resistant (MDR) tuberculosis

The Panel considered the risk to the UK from XDR- and MDR-tuberculosis (TB). In addition to written submissions from a range of national and international experts on the subject, presentations were given on the global threat of MDR- and XDR-TB, the current UK situation with regards to these infections and migrant demographic factors that might influence the emergence of XDR-TB in the UK.

Expert opinion varies on the precise magnitude of the risk that MDR- and XDR-TB poses to the UK. The Panel concluded that these infections are not an immediate or significant threat to the UK, although sporadic cases can be anticipated. However, members highlighted the importance of ensuring early access to treatment for TB for all TB patients, irrespective of immigration status.

The Panel expressed concern that at present there is no overarching independent panel responsible for TB. Various advisory committees have responsibility for aspects of TB, notably ARHAI for drug resistance issues; JCVI for vaccination policy. ACDP has TB within its overall remit for dangerous pathogens including for worker protection issues. Members noted that there was therefore potential for important issues to fall between these specialist committees .

### Meticillin resistant *Staphylococcus aureus* (MRSA) in animals

Members were informed that the Advisory Committee on Antimicrobial resistance and Healthcare Associated Infections (ARHAI) had reviewed the issue of MRSA in companion and food-producing animals and had provided a statement and guidance on the subject, available on the ARHAI website.

### Pandemic influenza

The Chair updated the Panel on the recent meetings and issues covered by the Pandemic Influenza Group. There were no specific issues for the Panel.

### West Nile Virus

The Panel was updated on recent human cases of West Nile Disease in Italy and Romania and in birds in Austria.

### **Summary list of letters written by the Chair**

#### Diagnostics for new and emerging viruses

The Chair of the NEPNEI wrote to the Chief Executive of the HPA on 15<sup>th</sup> July 2008 expressing the Panel's view that it is imperative for the HPA to maintain robust diagnostic services in order to promptly detect new and emerging viruses.

#### Hepatitis B and C antiviral resistance

The Chairs of the NEPNEI and the Advisory Group on Hepatitis wrote a joint letter to NICE on 5<sup>th</sup> August 2008, recommending a move towards the use of combination therapy for hepatitis to reduce antiviral resistance in Hepatitis B and C viruses.

## **ANNEX A – MEMBERSHIP 2008**

### **Chair**

**Professor Christopher Whitty**

### **Advisory Committee Chairs**

**Professor Janet Bainbridge**

Scientific Advisory Committee on Genetic Modification (contained use)  
(SACGM)

**Professor Roger Finch**

Advisory Committee on Antimicrobial Resistance and Healthcare Associated  
Infections (ARHAI)

**Professor Brian Gazzard**

Expert Advisory Group on Aids (EAGA)

**Professor George Griffin**

Advisory Committee on Dangerous Pathogens (ACDP)

**Professor Andrew Hall**

Joint Committee on Vaccination and Immunisation (JCVI)

**Professor Christopher Higgins**

Spongiform Encephalopathy Advisory Committee (SEAC)

**Professor Sarah O'Brien**

Advisory Committee on the Microbiological Safety of Food (ACMSF)

**Professor Howard Thomas**

Advisory Group on Hepatitis (AGH)

**Mr John Forsythe**

Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO)

### **Expert members and lay person**

**Professor Joe Brownlie**

Vet with zoonoses expertise

**Professor Christopher Butler**

General practitioner

**Professor Jon Friedland**

Infectious disease physician

**Professor Angela McLean**

Infectious disease modeller

**Professor Stephen Palmer**

HPA-nominated expert in the field of zoonoses and emerging hazards

**Dr Cathy Roth**

Coordinator, Emerging and Dangerous Pathogens, World Health Organization

**Dr John Watson**

Public health physician

**Mrs Catherine Beman**

Lay person

## ANNEX B: REGISTER OF MEMBERS' INTERESTS

Declarations of interest as of 1 July 2007 (unless stated)

<b>Professor Janet Bainbridge</b> Senior Vice-President Government and Europe, Centre for Process Innovation			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
			The supervision of occasional collaborative student project – no financial reward
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>		<i>Other</i>

<b>Mrs Catherine Beman</b> Lay member			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
none	none	none	none
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>		<i>Other</i>
none	none		none

<b>Professor Joe Brownlie</b> Professor of Veterinary Pathology, Department of Pathology & Infectious Diseases, The Royal Veterinary College, University of London			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
Occasional consultancy for Novartis Animal Health and Pfizer Animal Health companies regarding vaccine design and development.			n/a
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>		<i>Other</i>
	a. Research grant for bovine virus, diarrhoea virus vaccine development from Novartis Animal Vaccine Ltd. b. Research grant for canine respiratory corona virus vaccine development from Pfizer Animal Health vaccine		



<b>Professor Christopher Butler</b> Professor of Primary Care Medicine, Department of General Practice, Centre for Health Sciences Research, School of Medicine, Cardiff University			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	
	Pfizer has given a small grant for educational purposes (£10,000) for a research project being undertaken by a PhD student who I am supervising.		

<b>Professor Roger Finch</b> Professor of Infectious Diseases, School of Molecular Medical Sciences, University of Nottingham			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
Novartis/Cubist, ABRI(Switzerland), Mayne Pharmaceuticals, GlaxoSmithKline, ALCOS, Prolysis, Pfizer, Astellas, Wyeth	Lecture fees Bayer Wyeth		Travel grants Astellas Novartis Wyeth
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	

<b>Professor Jonathan Friedland</b> Professor of Infectious Diseases, Department of Infectious Diseases & Immunity, Faculty of Medicine, Imperial College			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
none	none	none	none
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	
		MSD sponsored a short course which I run at Imperial - "Update in Infectious Disease for Clinicians and Scientists". They have no involvement in course design.	

<b>Professor Brian Gazzard</b> Consultant Physician, Chelsea and Westminster Healthcare NHS Trust, St Stephen's Centre			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	
Nil	nil	nil	

<b>Professor George Griffin</b> Professor of Infectious Diseases and Medicine, Department of Cellular and Molecular Medicine, St George's Hospital Medical School			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
SAB Health Protection Agency (member)	Consultancy UCB/CellTech (UK/Belgium) Consultancy Biovail (Canada)	nil	nil
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	
nil	nil	nil	

<b>Professor Andrew Hall</b> Professor of Epidemiology, London School of Hygiene and Tropical Medicine			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
Non-executive director, Board of Health Protection Agency	none	none	none
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	
none	none	none	

<b>Professor Christopher Higgins</b> Vice-Chancellor, Durham University			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
	Chair – SEAC Human Genetics Commission	n/a	Employee – Durham University
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>		<i>Other</i>

<b>Professor Angela McLean</b> Professor of Mathematical Biology, Department of Zoology, University of Oxford			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
none	Member, Science Advisory Council, Defra	none	
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>		<i>Other</i>
none	none		

<b>Professor Sarah J O'Brien</b> Professor of Health Sciences and Epidemiology, Division of Medicine & Neurosciences – Hope, University of Manchester			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
none	none	none	
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>		<i>Other</i>
none	none		none

<b>Professor Stephen Palmer</b> Head of Department, Department of Epidemiology, Statistics and Public Health, Cardiff University			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
none	none	Prudential	
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	
Royal College of Physicians	none	none	
Faculty of Public Health			

<b>Professor Howard Thomas</b> Professor of Medicine/Head of Department, Department of Medicine A, Imperial College			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
Gilead Pharmaceuticals & BMS – clinical advice on chronic hepatitis B (US Advisory Group)  Non- executive director of Riontech Pharmaceuticals (Imperial College biotech spinout company): development of novel anti-virals		Founder of Riontech	
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>	<i>Industrial support</i>	<i>Other</i>	
	Funding to Department for clinical trials by Human Genome Science, Schering and Roche		

<b>Dr John Watson</b>			
Head of Respiratory Diseases Department , Respiratory Diseases Department, Health Protection Agency Centre For Infections			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
nil	nil	nil	nil
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>		<i>Industrial support</i>	<i>Other</i>
nil		nil	nil

<b>Professor Christopher Whitty</b>			
Professor of International Health and Director of the Malaria Centre at the London School of Hygiene & Tropical Medicine			
<b>Personal Interests:</b>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
none	none	none	none
<b>Non-Personal Interests:</b>			
<i>Fellowships</i>		<i>Industrial support</i>	<i>Other</i>
none		Grants for independent research from Pfizer and GSK.	none

**Declaration of interest as of 21 April 2008**

<p><b>Mr John Forsythe</b>                  Consultant Surgeon &amp; Clinical Director, Royal Infirmary of Edinburgh (Lothian University Hospitals Division)</p>			
<p><b>Personal Interests:</b></p>			
<i>Consultancies</i>	<i>Fee-paid work</i>	<i>Shareholdings</i>	<i>Other</i>
Non-executive Board Member NHS Quality Improvement Scotland 2002- 2007  Speciality Advisor to Chief Medical Officer, Scotland  Non-executive Board member NHS Blood & Transplant		none	none
<p><b>Non-Personal Interests:</b></p>			
<i>Fellowships</i>	<i>Industrial support</i>		<i>Other</i>
none	Honoria and grants received from Astellas PLC, Novartis PLC, Roche PLC, Wyeth PLC  Research carried out, partly supported by, roche PLC, Wyeth PLC, Astellas PLC and Novartis PLC. (No salary was received from any pharmaceutical group)		none

## **ANNEX C: AGENDAS FOR MEETINGS**

### **Tenth Meeting**

**10.15am, Thursday 5th June 2008**

- 1) Chairman's opening remarks
- 2) Introductions
- 3) Minutes of the 9th meeting
- 4) Matters arising and Secretariat report
- 5) DH research strategy
- 6) Members' concerns
- 7) HAIRS, zoonoses and roles and responsibilities of NEPNEI
- 8) The risk to the UK from XDR and MDR-TB
- 9) New Human Viruses and the UK's ability to detect them
- 10) AOB
- 11) Date of next meeting

## **Eleventh Meeting**

**10.15am, Thursday 27<sup>th</sup> November 2008**

- 1) Chairman's opening remarks
- 2) Introduction to SaBTO and current emerging issues
- 3) Minutes of 10th meeting
- 4) Matters arising and Secretariat's report
- 5) Novel arenavirus outbreak South Africa and Zambia (including a video conference with the National Institute for Communicable Disease, South Africa)
- 6) HAIRS, zoonoses and roles and responsibilities of NEPNEI
- 7) AOB



## ANNEX D: INDEX OF ABBREVIATIONS

<b>ABN</b>	Association of British Neurologists
<b>ACDP</b>	Advisory Committee on Dangerous Pathogens
<b>ACMSF</b>	Advisory Committee on the Microbiological Safety of Food
<b>AGH</b>	Advisory Group on Hepatitis
<b>ARHAI</b>	Antimicrobial Resistance and Healthcare Associated Infections
<b>BSE</b>	Bovine Spongiform Encephalopathy
<b>CDSC(NI)</b>	Communicable Disease Surveillance Centre Northern Ireland
<b>CMO</b>	Chief Medical Officer
<b>Defra</b>	Department of Environment, Food and Rural Affairs
<b>DARC</b>	Defra Antimicrobial Resistance Co-ordination group
<b>DH</b>	Department of Health
<b>EAGA</b>	Expert Advisory Group on Aids
<b>ESBL</b>	Extended spectrum B-lactamase
<b>FSA</b>	Food Standards Agency
<b>HAIRS</b>	Human Animal Infections Risk & Surveillance
<b>HIV</b>	Human Immunodeficiency Virus
<b>HPA</b>	Health Protection Agency
<b>HPS</b>	Health Protection Scotland
<b>HSE</b>	Health and Safety Executive
<b>IHR</b>	WHO International Health Regulations
<b>JCVI</b>	Joint Committee on Vaccination and Immunisation
<b>MDR-TB</b>	Multi-drug resistant tuberculosis
<b>MRSA</b>	Meticillin Resistant <i>Staphylococcus aureus</i>
<b>NEPNEI</b>	National Expert Panel on New and Emerging Infections
<b>NICE</b>	National Institute for Clinical Excellence
<b>PIN</b>	Progressive Inflammatory Neuropathy
<b>PVL</b>	Panton-Valentine Leukocidin
<b>SaBTO</b>	Advisory Committee on the Safety of Blood, Tissues and Organs
<b>SACAR</b>	Specialist Advisory Committee on Antimicrobial Resistance
<b>SACGM</b>	Scientific Advisory Committee on Genetic Modification (contained use)
<b>SEAC</b>	Spongiform Encephalopathy Advisory Committee

<b>TB</b>	Tuberculosis
<b>UK</b>	United Kingdom
<b>USA</b>	United States of America
<b>VLA</b>	Veterinary Laboratory Agency
<b>WHO</b>	World Health Organization
<b>XDR-TB</b>	Extensively Drug Resistant Tuberculosis